With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely be key in determining the impact of GLP-1s on plan costs.
This guide highlights what employers and benefits advisors should watch for in weight-management programs, and why a balanced, personalized approach always involves a behavior-change program.
Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been barriers to more widespread use by patients.